Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Covid-19 Vaccination - Federal Govt Approves Booster Dose

12/06/2021 | 02:06am EST

The Presidential Steering Committee (PSC) on COVID-19 in collaboration with the Federal Ministry of Health and the National Primary Health Care Development Agency (NPHCDA), has approved the administration of COVID-19 vaccine booster doses for persons that have completed two doses of AstraZeneca, Moderna, Pfizer Bio-N-Tech or one dose of Johnson & Johnson.

According to a statement signed by the head, public relations unit, NPHCDA, Mohammad Ohitoto, Friday night, the executive director/CEO, NPHCDA, Dr. Faisal Shuaib, said the eligibility criteria for taking the booster dose are any person of 18 years and above, time interval of six months or more after receiving the second dose of AstraZeneca, Moderna or Pfizer Bio-N-Tech and time interval of two months or more after receiving the Johnson and Johnson vaccine.

He said consequent upon the development, eligible Nigerians are advised to visit the nearest health facility or mass vaccination site for their booster doses as from the 10th of December, 2021 across all states of the federation.

Shuaib explained that a COVID-19 booster dose gives greater protection against the virus and urged all Nigerians to take advantage of the opportunity offered by the federal government.

He said the list of the vaccination sites is available on the NPHCDA website: www.nphcda.gov.ng.

Copyright Leadership. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.72% 8459 Delayed Quote.-4.17%
JOHNSON & JOHNSON 2.99% 167.64 Delayed Quote.-4.73%
MODERNA, INC. -0.38% 155.88 Delayed Quote.-38.07%
All news about ASTRAZENECA PLC
02:02pValneva Starts Extended Trial to Study Booster Shot of COVID-19 Vaccine; Shares Up 9%
MT
04:32aOrange Corners South Africa and AstraZeneca South Africa join forces in a new partnersh..
AQ
04:31aGermany to receive 3.8 mln doses of Novavax's new COVID vaccine in Q1
RE
03:44aOrange Corners South Africa and AstraZeneca South Africa join forces in a new partnersh..
AQ
02:01aEgetis appoints Karl Hård as Head of Investor Relations and Communication
AQ
01/24PCI Biotech Loses 10% As It Discontinues Cancer Trial To Focus On Immunotherapies
MT
01/24AstraZeneca's Rare Progressive Disease Drug Granted US FDA Orphan Drug Tag
MT
01/24Sinovac regimen gets strong boost from Pfizer, AstraZeneca or J&J COVID shots - study
RE
01/24Chile to purchase 2 million Moderna COVID-19 vaccine doses
RE
01/24AstraZeneca Gets European Medicines Agency's Approval to Ramp Up COVID-19 Vaccine Manuf..
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 220 M - -
Net income 2021 2 516 M - -
Net Debt 2021 24 757 M - -
P/E ratio 2021 56,3x
Yield 2021 2,50%
Capitalization 177 B 177 B -
EV / Sales 2021 5,56x
EV / Sales 2022 4,56x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 112,17 $
Average target price 138,82 $
Spread / Average Target 23,8%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC-4.17%173 383
JOHNSON & JOHNSON-4.73%429 034
ROCHE HOLDING AG-9.06%304 714
PFIZER, INC.-12.72%289 287
ABBVIE INC.-2.39%233 643
ELI LILLY AND COMPANY-12.00%217 963